More positive news on HCQ.
techstartups.com
According to a new study published in American Journal of Epidemiology, early outpatient treatment is the most effective for treatment of coronavirus patients. The study, which was led by Dr. Harvey A Risch of Yale University, suggests that late stage studies missed the point about effective usage of hydroxychloroquine. Dr. Risch says immediate and early ramping-up of treatment for high-risk COVID-19 patients is key to controlling the coronavirus pandemic crisis.
To date, more than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality.
According to the abstract of the study, which has not yet been peer-reviewed, Dr. Risch said an outpatient treatment that prevents hospitalization is desperately needed. To date, two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. “Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September,” Dr. Harvey A Risch of Yale University, said.
In a 29-page report, the study suggests that early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease.
Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000
...
In reviewing all available evidence, I will show that HCQ+AZ and HCQ+doxycycline are generally safe for short-term use in the early treatment of most symptomatic high-risk outpatients, where not contraindicated, and that they are
effective in preventing hospitalization for the overwhelming majority of such patients. If these combined medications become standard-of-care, they are likely to save an enormous number of lives that would otherwise be lost to this endemic disease.
...
To date, more than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality.
According to the abstract of the study, which has not yet been peer-reviewed, Dr. Risch said an outpatient treatment that prevents hospitalization is desperately needed. To date, two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. “Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September,” Dr. Harvey A Risch of Yale University, said.
In a 29-page report, the study suggests that early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease.
Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000
...
In reviewing all available evidence, I will show that HCQ+AZ and HCQ+doxycycline are generally safe for short-term use in the early treatment of most symptomatic high-risk outpatients, where not contraindicated, and that they are
effective in preventing hospitalization for the overwhelming majority of such patients. If these combined medications become standard-of-care, they are likely to save an enormous number of lives that would otherwise be lost to this endemic disease.
...

New hydroxychloroquine study: Early outpatient treatment is the most effective for treatment of COVID-19 patients, Dr. Harvey A Risch of Yale University says | Tech News | Startups News
According to a new study published in American Journal of Epidemiology, early outpatient treatment is the most effective for treatment of coronavirus patients. The study, which was led by Dr. Harvey A Risch of Yale University, suggests that late stage studies missed …
